secwatch.observer — SEC 8-K summary
======================================

Issuer:     Protara Therapeutics, Inc. (TARA)
CIK:        0001359931
Form:       8-K
Filed at:   2024-03-18T23:59:59+00:00
Accession:  0001213900-24-023589
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Protara CMO Jathin Bandari resigns effective April 11; interim oversight assigned
--------------------------------------------------------------------------------

- CMO Jathin Bandari resigns effective April 11, 2024 to explore academic opportunities; consulting through July 11.
- Severance includes $365,386 lump sum (9 months salary), $164,424 bonus, COBRA for 9 months, and pro-rata vesting of 11,993 options + 5,886 RSUs.
- Interim oversight: Jacqueline Zummo (SVP & Chief Scientific Ops Officer) leads medical staff, advised by board member Richard Levy, M.D.
- Company plans to search for a new Chief Medical Officer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1359931/000121390024023589/0001213900-24-023589-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1359931/000121390024023589/ea0202028-8k_protara.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-023589

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer